Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

from Reuters: Health https://ift.tt/2OOfQ2R
via IFTTT

• Tweet
• Share
• Share
• Share
• Share